Kliiniset tutkimukset Nct sivu

Summary
EudraCT Number:2004-002945-10
Sponsor's Protocol Code Number:V501-020
Clinical Trial Type:Outside EU/EEA
Date on which this record was first entered in the EudraCT database:2011-07-21
Trial results View results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
H.4 THIRD COUNTRY IN WHICH THE TRIAL WAS FIRST AUTHORISED
A. Protocol Information
A.2EudraCT number2004-002945-10
A.3Full title of the trial
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16,
and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-,11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-,11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men
A.4.1Sponsor's protocol code numberV501-020
A.5.2US NCT (ClinicalTrials.gov registry) numberNCT00090285
A.7Trial is part of a Paediatric Investigation Plan No
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
B.1.3.4CountryUnited States
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
B.4.2CountryUnited States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
B.5.2Functional name of contact pointAlain Luxembourg
B.5.3 Address:
B.5.3.1Street AddressOne Merck Drive - P.O. Box 100
B.5.3.2Town/ cityWhitehouse Station, NJ
B.5.3.3Post code08889-0100
B.5.3.4CountryUnited States
B.5.6E-mailalain_luxembourg@merck.com
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Yes
D.2.1.1.1Trade name GARDASIL™/SILGARD™
D.2.1.1.2Name of the Marketing Authorisation holderMSD VACCINS
D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.4Pharmaceutical form Suspension for injection
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPIntramuscular use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNHuman Papillomavirus Type 6 L1 protein
D.3.9.3Other descriptive nameHPV 6 TYPE L1 PROTEIN ADS. ON AMORPHOUS ALUMINIUM HYDROXYPHOSPHATE SULPHATE [PROD. IN S. CEREVISIAE CANADE3C-5 (STRAIN 1895) BY RECOM. DNA TECHNOL.]
D.3.9.4EV Substance CodeSUB25327
D.3.10 Strength
D.3.10.1Concentration unit µg microgram(s)
D.3.10.2Concentration typeequal
D.3.10.3Concentration number20
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNHuman Papillomavirus Type 11 L1 protein
D.3.9.3Other descriptive nameHPV TYPE 11 L1 PROTEIN ADS. ON AMORPHOUS ALUMINIUM HYDROXYPHOSPHATE SULPHATE [PROD. IN S. CEREVISIAE CANADE3C-5 (STRAIN 1895) BY RECOM. DNA TECHNOL.]
D.3.9.4EV Substance CodeSUB25330
D.3.10 Strength
D.3.10.1Concentration unit µg microgram(s)
D.3.10.2Concentration typeequal
D.3.10.3Concentration number40
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNHuman Papillomavirus Type 16 L1 protein
D.3.9.3Other descriptive nameHPV TYPE 16 L1 PROTEIN ADS. ON AMORPHOUS ALUMINIUM HYDROXYPHOSPHATE SULPHATE [PROD. IN S. CEREVISIAE CANADE3C-5 (STRAIN 1895) BY RECOM. DNA TECHNOL.]
D.3.9.4EV Substance CodeSUB25329
D.3.10 Strength
D.3.10.1Concentration unit µg microgram(s)
D.3.10.2Concentration typeequal
D.3.10.3Concentration number40
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNHuman Papillomavirus Type 18 L1 protein
D.3.9.3Other descriptive nameHPV TYPE 18 L1 PROTEIN ADS. ON AMORPHOUS ALUMINIUM HYDROXYPHOSPHATE SULPHATE [PROD. IN S. CEREVISIAE CANADE3C-5 (STRAIN 1895) BY RECOM. DNA TECHNOL.]
D.3.9.4EV Substance CodeSUB25328
D.3.10 Strength
D.3.10.1Concentration unit µg microgram(s)
D.3.10.2Concentration typeequal
D.3.10.3Concentration number20
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product No
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
D.8 Placebo: 1
D.8.1Is a Placebo used in this Trial?Yes
D.8.3Pharmaceutical form of the placeboSuspension for injection
D.8.4Route of administration of the placeboIntramuscular use
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Prevention of Human Papillomavirus Infections
E.1.1.1Medical condition in easily understood language
Genital Warts and anal cancer/precancer
E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 20.1
E.1.2Level LLT
E.1.2Classification code 10063001
E.1.2Term Human papilloma virus infection
E.1.2System Organ Class 100000004862
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
Base study/first extension
Safety: To demonstrate that a 3-dose regimen of GARDASIL (0, 2, 6 mo), is well tolerated in young men.
Efficacy: To demonstrate that a 3-dose regimen of GARDASIL reduces the incidence of HPV 6-,11-,16-, or 18-related external genital warts, PIN, penile, perianal or perineal cancer in young men who are naïve to the relevant HPV type, compared with placebo.

LTFU:
To estimate the long-term effectiveness of qHPV vaccine with respect to the incidence of: 1. HPV 6/11-related external genital warts in young men during a period of 10 years 2. HPV 6/11/16/18-related external genital lesions, including genital warts, penile, perianal, and PIN or penile, perianal, and perineal cancer in young men during a period of 10 years. 3. HPV 6/11/16/18-related AIN and anal cancer in young MSM during a period of 10 years.
To describe incidence of vaccine/procedure-related serious adverse experiences and incidence of deaths in young men who received qHPV vaccine
E.2.2Secondary objectives of the trial
Base study/first extension
Efficacy: (1) To demonstrate that GARDASIL - 3-dose regimen, reduces the incidence of persistent HPV 6, 11, 16, or 18 infection in young men who are naïve to the relevant HPV type, compared with placebo (2) To demonstrate that GARDASIL- 3-dose regimen, reduces the incidence of HPV 6, 11, 16, or 18 DNA detection at 1 or more visits, in young men who are naïve to the relevant HPV type, compared with placebo.
Immunogenicity: To evaluate the vaccine-induced serum anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 responses in young men.

LTFU:
Immunogenicity: To evaluate, using the cLIA assay, anti-HPV 6, 11, 16, and 18 immune responses to a 3-dose regimen of qHPV vaccine, for up to 10 years after enrollment in the base study.
E.2.3Trial contains a sub-study Yes
E.2.3.1Full title, date and version of each sub-study and their related objectives
MSM Substudy Efficacy Objective: To investigate the impact of administration of a 3-dose regimen of GARDASIL™ on the combined incidence of HPV 6-, 11-, 16-, or 18-related Anal Intraepithelial Neoplasia (AIN) or Anal Cancer in Men Having Sex with Men (MSM) who are naïve to the relevant HPV type.
E.3Principal inclusion criteria
•Healthy heterosexual males between the ages of 16 years and 23 years and 364 days. Healthy men having sex with men (MSM) between the ages of 16 years and 26 years and 364 days.
•No clinical evidence of genital lesions suggesting sexually-transmitted disease, and no history of anogenital warts
•Additional criteria will be discussed with you by the physician
E.4Principal exclusion criteria
•Concurrently enrolled in a clinical study involving collection of genital specimens
•History of known prior vaccination with an HPV vaccine
•Received an inactivated vaccine within 14 days or a live virus vaccine within 21 days prior to enrollment
•History of a severe allergic reaction that required medical intervention
•Received any immune globulin or blood-derived products within 6 months prior to the first study injection
•History of splenectomy, immune disorders, or receiving immunosuppressives
•Immunocompromised or diagnosed with HIV infection
•Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
•History of recent or ongoing alcohol or drug abuse
E.5 End points
E.5.1Primary end point(s)
1.Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer
2.Overall Study: Incidence of HPV Type 6/11-related Genital Warts
3.Overall Study: Incidence of HPV Type 6/11/16/18-related External Genital Warts, PIN, Penile, Perianal or Perineal Cancer
4.Overall Study: Incidence of HPV Type 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer
5.Base Study: Number of Participants With Severe Injection Site Adverse Experiences (AEs)
6.Base Study: Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)
7.LTFU (EXT2): Number of Participants With Vaccine-Related SAEs
8.LTFU (EXT2): Number of Participants Who Died
E.5.1.1Timepoint(s) of evaluation of this end point
1. and 6: Base study: through Month 36
2. to 4: Up to 10 years after the first dose of qHPV vaccine
5: Base study: through Day 5 after any vaccination
7. and 8: LTFU (EXT2): Early Vaccination Group: up to 12 years after last dose of qHPV vaccine; LTFU (EXT2) Catch-up Vaccination Group: up to 7 years after last dose of qHPV vaccine
E.5.2Secondary end point(s)
1.Base Study: Incidence of HPV 6/11/16/18-related Persistent Infection
2.Base Study: Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection
3.Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 7 Assessed by Competitive Luminex Immunoassay (cLIA)
4.Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA
5.Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 72 Assessed by cLIA
6.Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 120 Assessed by cLIA
7.Percentage of Participants Seropositive for HPV Type 6, 11, 16, and 18 at Month 7 Assessed by cLIA
8.Percentage of Participants Seropositive for HPV Type 6, 11, 16, and 18 at Month 36 Assessed by cLIA
9.Percentage of Participants Seropositive for HPV Type 6, 11, 16, and 18 at Month 72 Assessed by cLIA
10.Percentage of Participants Seropositive for HPV Type 6, 11, 16, and 18 at Month 120 Assessed by cLIA
11.Geometric Mean Titers to HPV Types 6, 11, 16, and 18 at Month 120 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
12.Percentage of Participants Seropositive for HPV Type 6, 11, 16, and 18 at Month 120 Assessed by IgG LIA
E.5.2.1Timepoint(s) of evaluation of this end point
1. and 2.: Base study: through Month 36
3. and 7: Month 7
4. and 8: Month 36
5. and 9: Month 72
6., 10, 11 and 12: Month 120
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis Yes
E.6.3Therapy No
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others Yes
E.6.13.1Other scope of the trial description
Participants were followed in EXT1 for 7 months. In EXT 2 [LTFU (EXT2)], long-term effectiveness, immunogenicity, and safety of qHPV vaccine were followed up to 10 years
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) Yes
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open No
E.8.1.3Single blind No
E.8.1.4Double blind Yes
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo Yes
E.8.2.3Other No
E.8.2.4Number of treatment arms in the trial2
E.8.3 Will this trial be conducted at a single site globally? No
E.8.4 Will this trial be conducted at multiple sites globally? Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.2Trial being conducted completely outside of the EEA No
E.8.6.3Specify the countries outside of the EEA in which trial sites are planned
Australia
Brazil
Canada
Costa Rica
Mexico
Peru
Philippines
South Africa
Taiwan
United States
E.8.7Trial has a data monitoring committee No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
For purposes of analysis and reporting, the overall trial ends when the Sponsor receives the last assay results (e.g. serum, swab, and biopsy) or subject/patient data from the last study related phone-call or visit.
E.8.9 Initial estimate of the duration of the trial
E.8.9.2In all countries concerned by the trial years3
E.8.9.2In all countries concerned by the trial months3
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1Number of subjects for this age range: 187
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.5Children (2-11years) No
F.1.1.6Adolescents (12-17 years) Yes
F.1.1.6.1Number of subjects for this age range: 187
F.1.2Adults (18-64 years) Yes
F.1.2.1Number of subjects for this age range: 3878
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female No
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers Yes
F.3.2Patients No
F.3.3Specific vulnerable populations No
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally No
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.2 For a multinational trial
F.4.2.2In the whole clinical trial 4065
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
none
G. Investigator Networks to be involved in the Trial
H.4 Third Country in which the Trial was first authorised
H.4.1Third Country in which the trial was first authorised: United States

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa